AstraZeneca will present new clinical and scientific data on its entire portfolio of vaccines and immune therapies at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain, April 27-30, 2024.

' The company will present 19 abstracts at the event that will highlight the continuing need to protect at-risk individuals from the increased burden of common infectious diseases and the important role of long-acting antibodies and vaccines ' says the group.

Data will be presented in particular on the efficacy of Beyfortus (nirsevimab), a long-acting antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV).

Data will also be presented on sipavibart, an experimental long-acting antibody for the prevention of COVID-19 in immunocompromised people.

Iskra Reic, Executive Vice President, Vaccines and Immunotherapies, AstraZeneca, said: 'We are proud of the difference our preventive therapies are making in reducing the burden of respiratory infections, with new real-world data highlighting the efficacy of our long-acting antibody Beyfortus in preventing childhood hospitalizations due to RSV.'

"In addition, our data provide evidence that immunocompromised individuals continue to face a significant and disproportionate burden of COVID-19, underscoring the need for additional protection."

Copyright (c) 2024 All rights reserved.